A multi-omics analysis reveals CLSPN is associated with prognosis, immune microenvironment and drug resistance in cancers
© 2023. The Author(s)..
BACKGROUND: Immunotherapy is effective only in limited patients. It is urgent to discover a novel biomarker to predict immune cells infiltration status and immunotherapy response of different cancers. CLSPN has been reported to play a pivotal role in various biological processes. However, a comprehensive analysis of CLSPN in cancers has not been conducted.
METHODS: To show the whole picture of CLSPN in cancers, a pan-cancer analysis was conducted in 9125 tumor samples across 33 cancer types by integrating transcriptomic, epigenomic and pharmacogenomics data. Moreover, the role of CLSPN in cancer was validated by CCK-8, EDU, colony formation and flow cytometry in vitro and tumor cell derived xenograft model in vivo.
RESULTS: CLSPN expression was generally upregulated in most cancer types and was significantly associated with prognosis in different tumor samples. Moreover, elevated CLSPN expression was closely correlated with immune cells infiltration, TMB (tumor mutational burden), MSI (microsatellite instability), MMR (mismatch repair), DNA methylation and stemness score across 33 cancer types. Enrichment analysis of functional genes revealed that CLSPN participated in the regulation of numerous signaling pathways involved in cell cycle and inflammatory response. The expression of CLSPN in LUAD patients were further analyzed at the single-cell level. Knockdown CLSPN significantly inhibited cancer cell proliferation and cell cycle related cyclin-dependent kinase (CDK) family and Cyclin family expression in LUAD (lung adenocarcinoma) both in vitro and in vivo experiments. Finally, we conducted structure-based virtual screening by modelling the structure of CHK1 kinase domain and Claspin phosphopeptide complex. The top five hit compounds were screened and validated by molecular docking and Connectivity Map (CMap) analysis.
CONCLUSION: Our multi-omics analysis offers a systematic understanding of the roles of CLSPN in pan-cancer and provides a potential target for future cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Biological procedures online - 25(2023), 1 vom: 03. Juni, Seite 16 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Yihong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CLSPN |
|---|
| Anmerkungen: |
Date Revised 05.06.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s12575-023-00201-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357709268 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357709268 | ||
| 003 | DE-627 | ||
| 005 | 20231226073157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12575-023-00201-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357709268 | ||
| 035 | |a (NLM)37268895 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Yihong |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A multi-omics analysis reveals CLSPN is associated with prognosis, immune microenvironment and drug resistance in cancers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.06.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Immunotherapy is effective only in limited patients. It is urgent to discover a novel biomarker to predict immune cells infiltration status and immunotherapy response of different cancers. CLSPN has been reported to play a pivotal role in various biological processes. However, a comprehensive analysis of CLSPN in cancers has not been conducted | ||
| 520 | |a METHODS: To show the whole picture of CLSPN in cancers, a pan-cancer analysis was conducted in 9125 tumor samples across 33 cancer types by integrating transcriptomic, epigenomic and pharmacogenomics data. Moreover, the role of CLSPN in cancer was validated by CCK-8, EDU, colony formation and flow cytometry in vitro and tumor cell derived xenograft model in vivo | ||
| 520 | |a RESULTS: CLSPN expression was generally upregulated in most cancer types and was significantly associated with prognosis in different tumor samples. Moreover, elevated CLSPN expression was closely correlated with immune cells infiltration, TMB (tumor mutational burden), MSI (microsatellite instability), MMR (mismatch repair), DNA methylation and stemness score across 33 cancer types. Enrichment analysis of functional genes revealed that CLSPN participated in the regulation of numerous signaling pathways involved in cell cycle and inflammatory response. The expression of CLSPN in LUAD patients were further analyzed at the single-cell level. Knockdown CLSPN significantly inhibited cancer cell proliferation and cell cycle related cyclin-dependent kinase (CDK) family and Cyclin family expression in LUAD (lung adenocarcinoma) both in vitro and in vivo experiments. Finally, we conducted structure-based virtual screening by modelling the structure of CHK1 kinase domain and Claspin phosphopeptide complex. The top five hit compounds were screened and validated by molecular docking and Connectivity Map (CMap) analysis | ||
| 520 | |a CONCLUSION: Our multi-omics analysis offers a systematic understanding of the roles of CLSPN in pan-cancer and provides a potential target for future cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CLSPN | |
| 650 | 4 | |a Immune infiltration | |
| 650 | 4 | |a Multi-omics | |
| 650 | 4 | |a Pan-cancer | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Virtual screening | |
| 700 | 1 | |a Wen, Haicheng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yin |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Cao |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Changjing |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Yinghui |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yihan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xinwen |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Ziyang |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Hong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biological procedures online |d 1998 |g 25(2023), 1 vom: 03. Juni, Seite 16 |w (DE-627)NLM125032137 |x 1480-9222 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:1 |g day:03 |g month:06 |g pages:16 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12575-023-00201-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 1 |b 03 |c 06 |h 16 | ||